BioStem Technologies, Inc. cash flow to debt ratio of 298.43% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

BioStem Technologies, Inc.'s free cash flow has decreased 72.60% from $24.05M last year to $6.59M, signaling decreasing performance

BioStem Technologies, Inc.'s debt to equity ratio is 0.04, which means that the company's assets are healthy financed, signaling financial stability.

BioStem Technologies, Inc.'s debt has decreased relative to shareholder equity from 0.11 last year to 0.04 today, signaling strengthened financials

BioStem Technologies, Inc. has a net cash position, so leverage is healthy.

BioStem Technologies, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

BioStem Technologies, Inc.'s profit margin was 10.56% last year and is 46.91% this year, signaling increasing performance

BioStem Technologies, Inc.'s short-term assets of $44.40M exceed its short-term liabilities of $10.78M

BioStem Technologies, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

BioStem Technologies, Inc.'s return on equity of -76.13%, is lower than 15.00%, indicating bad performance

BioStem Technologies, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

BioStem Technologies, Inc. had positive net income in only 1 out of 5 years, indicating unstable earnings

BioStem Technologies, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

BioStem Technologies, Inc. has a free cash flow yield of 14.21%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

BioStem Technologies, Inc.'s yearly earnings has decreased 120.64% since last year from $31.88M to $-6.58M, signaling decreasing performance

BioStem Technologies, Inc.'s yearly revenue has decreased 84.27% since last year from $301.83M to $47.48M, signaling decreasing performance

ROIC -80.92% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

BioStem Technologies, Inc.'s 3-year revenue CAGR of 90.44% is positive, indicating growing revenue over the past 3 years

BioStem Technologies, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

BioStem Technologies, Inc. had positive ROE in only 1 out of 5 years, indicating inconsistent returns on equity

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioStem Technologies, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

BioStem Technologies, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

BioStem Technologies, Inc. has insufficient data to evaluate this check.

BioStem Technologies, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

BioStem Technologies, Inc. has a price-to-book ratio of 1.71x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

BioStem Technologies, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue